Literature DB >> 24300897

PLC-γ and PI3K link cytokines to ERK activation in hematopoietic cells with normal and oncogenic Kras.

Ernesto Diaz-Flores1, Hana Goldschmidt, Philippe Depeille, Victor Ng, Jon Akutagawa, Kimberly Krisman, Michael Crone, Michael R Burgess, Olusegun Williams, Benjamin Houseman, Kevan Shokat, Deepak Sampath, Gideon Bollag, Jeroen P Roose, Benjamin S Braun, Kevin Shannon.   

Abstract

Oncogenic K-Ras proteins, such as K-Ras(G12D), accumulate in the active, guanosine triphosphate (GTP)-bound conformation and stimulate signaling through effector kinases. The presence of the K-Ras(G12D) oncoprotein at a similar abundance to that of endogenous wild-type K-Ras results in only minimal phosphorylation and activation of the canonical Raf-mitogen-activated or extracellular signal-regulated protein kinase kinase (MEK)-extracellular signal-regulated kinase (ERK) and phosphoinositide 3-kinase (PI3K)-Akt-mammalian target of rapamycin (mTOR) signaling cascades in primary hematopoietic cells, and these pathways remain dependent on growth factors for efficient activation. We showed that phospholipase C-γ (PLC-γ), PI3K, and their generated second messengers link activated cytokine receptors to Ras and ERK signaling in differentiated bone marrow cells and in a cell population enriched for leukemia stem cells. Cells expressing endogenous oncogenic K-Ras(G12D) remained dependent on the second messenger diacylglycerol for the efficient activation of Ras-ERK signaling. These data raise the unexpected possibility of therapeutically targeting proteins that function upstream of oncogenic Ras in cancer.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24300897      PMCID: PMC4117477          DOI: 10.1126/scisignal.2004125

Source DB:  PubMed          Journal:  Sci Signal        ISSN: 1945-0877            Impact factor:   8.192


  61 in total

1.  Inhibiting the palmitoylation/depalmitoylation cycle selectively reduces the growth of hematopoietic cells expressing oncogenic Nras.

Authors:  Jin Xu; Christian Hedberg; Frank J Dekker; Qing Li; Kevin M Haigis; Eugene Hwang; Herbert Waldmann; Kevin Shannon
Journal:  Blood       Date:  2011-12-05       Impact factor: 22.113

2.  Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activity.

Authors:  Till Maurer; Lindsay S Garrenton; Angela Oh; Keith Pitts; Daniel J Anderson; Nicholas J Skelton; Benjamin P Fauber; Borlan Pan; Shiva Malek; David Stokoe; Mary J C Ludlam; Krista K Bowman; Jiansheng Wu; Anthony M Giannetti; Melissa A Starovasnik; Ira Mellman; Peter K Jackson; Joachim Rudolph; Weiru Wang; Guowei Fang
Journal:  Proc Natl Acad Sci U S A       Date:  2012-03-19       Impact factor: 11.205

Review 3.  Focus on myeloproliferative diseases and myelodysplastic syndromes.

Authors:  Richard A Van Etten; Kevin M Shannon
Journal:  Cancer Cell       Date:  2004-12       Impact factor: 31.743

4.  KIT exon 8 mutations associated with core-binding factor (CBF)-acute myeloid leukemia (AML) cause hyperactivation of the receptor in response to stem cell factor.

Authors:  Tobias M Kohl; Susanne Schnittger; Joachim W Ellwart; Wolfgang Hiddemann; Karsten Spiekermann
Journal:  Blood       Date:  2004-12-23       Impact factor: 22.113

5.  Functional analysis of leukemia-associated PTPN11 mutations in primary hematopoietic cells.

Authors:  Suzanne Schubbert; Kenneth Lieuw; Sara L Rowe; Connie M Lee; Xiaxin Li; Mignon L Loh; D Wade Clapp; Kevin M Shannon
Journal:  Blood       Date:  2005-03-10       Impact factor: 22.113

6.  Nf1 and Gmcsf interact in myeloid leukemogenesis.

Authors:  R A Birnbaum; A O'Marcaigh; Z Wardak; Y Y Zhang; G Dranoff; T Jacks; D W Clapp; K M Shannon
Journal:  Mol Cell       Date:  2000-01       Impact factor: 17.970

7.  RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth.

Authors:  Georgia Hatzivassiliou; Kyung Song; Ivana Yen; Barbara J Brandhuber; Daniel J Anderson; Ryan Alvarado; Mary J C Ludlam; David Stokoe; Susan L Gloor; Guy Vigers; Tony Morales; Ignacio Aliagas; Bonnie Liu; Steve Sideris; Klaus P Hoeflich; Bijay S Jaiswal; Somasekar Seshagiri; Hartmut Koeppen; Marcia Belvin; Lori S Friedman; Shiva Malek
Journal:  Nature       Date:  2010-02-03       Impact factor: 49.962

8.  Human somatic PTPN11 mutations induce hematopoietic-cell hypersensitivity to granulocyte-macrophage colony-stimulating factor.

Authors:  Rebecca J Chan; Melissa B Leedy; Veerendra Munugalavadla; Cara S Voorhorst; Yanjun Li; Menggang Yu; Reuben Kapur
Journal:  Blood       Date:  2005-01-11       Impact factor: 22.113

9.  Dysregulated RasGRP1 responds to cytokine receptor input in T cell leukemogenesis.

Authors:  Catherine Hartzell; Olga Ksionda; Ed Lemmens; Kristen Coakley; Ming Yang; Monique Dail; Richard C Harvey; Christopher Govern; Jeroen Bakker; Tineke L Lenstra; Kristin Ammon; Anne Boeter; Stuart S Winter; Mignon Loh; Kevin Shannon; Arup K Chakraborty; Matthias Wabl; Jeroen P Roose
Journal:  Sci Signal       Date:  2013-03-26       Impact factor: 8.192

10.  Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF.

Authors:  Sonja J Heidorn; Carla Milagre; Steven Whittaker; Arnaud Nourry; Ion Niculescu-Duvas; Nathalie Dhomen; Jahan Hussain; Jorge S Reis-Filho; Caroline J Springer; Catrin Pritchard; Richard Marais
Journal:  Cell       Date:  2010-01-22       Impact factor: 41.582

View more
  9 in total

Review 1.  Mechanistic and Preclinical Insights from Mouse Models of Hematologic Cancer Characterized by Hyperactive Ras.

Authors:  Anica Wandler; Kevin Shannon
Journal:  Cold Spring Harb Perspect Med       Date:  2018-04-02       Impact factor: 6.915

2.  Stat5 is critical for the development and maintenance of myeloproliferative neoplasm initiated by Nf1 deficiency.

Authors:  Zohar Sachs; Raha A Been; Krista J DeCoursin; Hanh T Nguyen; Nurul A Mohd Hassan; Klara E Noble-Orcutt; Craig E Eckfeldt; Emily J Pomeroy; Ernesto Diaz-Flores; Jennifer L Geurts; Miechaleen D Diers; Diane E Hasz; Kelly J Morgan; Margaret L MacMillan; Kevin M Shannon; David A Largaespada; Stephen M Wiesner
Journal:  Haematologica       Date:  2016-07-14       Impact factor: 9.941

3.  Novel therapeutic approaches for pancreatic cancer by combined targeting of RAF→MEK→ERK signaling and autophagy survival response.

Authors:  Faustino Mollinedo; Consuelo Gajate
Journal:  Ann Transl Med       Date:  2019-07

4.  Ras-related C3 Botulinum Toxin Substrate (Rac) and Src Family Kinases (SFK) Are Proximal and Essential for Phosphatidylinositol 3-Kinase (PI3K) Activation in Natural Killer (NK) Cell-mediated Direct Cytotoxicity against Cryptococcus neoformans.

Authors:  Richard F Xiang; Danuta Stack; Shaunna M Huston; Shu Shun Li; Henry Ogbomo; Stephen K Kyei; Christopher H Mody
Journal:  J Biol Chem       Date:  2016-02-11       Impact factor: 5.157

5.  Urotensin-II receptor stimulation of cardiac L-type Ca2+ channels requires the βγ subunits of Gi/o-protein and phosphatidylinositol 3-kinase-dependent protein kinase C β1 isoform.

Authors:  Yuan Zhang; Jiaoqian Ying; Dongsheng Jiang; Zhigang Chang; Hua Li; Guoqiang Zhang; Shan Gong; Xinghong Jiang; Jin Tao
Journal:  J Biol Chem       Date:  2015-02-12       Impact factor: 5.157

6.  Targeting the PI3K/Akt pathway in murine MDS/MPN driven by hyperactive Ras.

Authors:  J Akutagawa; T Q Huang; I Epstein; T Chang; M Quirindongo-Crespo; C L Cottonham; M Dail; B S Slusher; L S Friedman; D Sampath; B S Braun
Journal:  Leukemia       Date:  2016-02-12       Impact factor: 11.528

7.  Survival of pancreatic cancer cells lacking KRAS function.

Authors:  Mandar Deepak Muzumdar; Pan-Yu Chen; Kimberly Judith Dorans; Katherine Minjee Chung; Arjun Bhutkar; Erin Hong; Elisa M Noll; Martin R Sprick; Andreas Trumpp; Tyler Jacks
Journal:  Nat Commun       Date:  2017-10-23       Impact factor: 14.919

8.  Tonic ATP-mediated growth suppression in peripheral nerve glia requires arrestin-PP2 and is evaded in NF1.

Authors:  Robert A Coover; Tabitha E Healy; Li Guo; Katherine E Chaney; Robert F Hennigan; Craig S Thomson; Lindsey E Aschbacher-Smith; Michael P Jankowski; Nancy Ratner
Journal:  Acta Neuropathol Commun       Date:  2018-11-23       Impact factor: 7.801

9.  Inhibiting ERK Activation with CI-1040 Leads to Compensatory Upregulation of Alternate MAPKs and Plasminogen Activator Inhibitor-1 following Subtotal Nephrectomy with No Impact on Kidney Fibrosis.

Authors:  Faith Hannah Nutter; John L Haylor; Arif Khwaja
Journal:  PLoS One       Date:  2015-09-28       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.